Immuno-Oncology | Specialty

Sznol Reflects on Immunotherapy Advances in mRCC

August 9th 2018

Mario Sznol, MD, discusses the latest developments with immunotherapy in metastatic renal cell carcinoma.

Dr. Bota on Marizomib in Patients with Glioma

August 8th 2018

Daniela Bota, MD, PhD, medical director, Neuro-Oncology Program, associate professor, Neurology School of Medicine, UC Irvine Health, discusses marizomib for the treatment of patients with glioma.

Expert Highlights Role of TMB in Evolving Immuno-Oncology Landscape

August 8th 2018

Conor E. Steuer, MD, shares insight on the emerging role of tumor mutational burden in relation to immunotherapy for patients with cancer.

Borghaei Discusses Nivolumab/Ipilimumab CheckMate-227 NSCLC Findings

August 6th 2018

Hossein Borghaei, DO, MS, discusses the results of the subgroup analysis of the ongoing CheckMate-227 trial in metastatic non–small cell lung cancer.

Dr. Galsky on Neoadjuvant Immune Checkpoint Blockade in Bladder Cancer

August 3rd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses neoadjuvant immune checkpoint inhibition in patients with bladder cancer.

Dr. Langer on the Impact of Frontline Immunotherapy in Lung Cancer

August 3rd 2018

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of frontline immunotherapy in lung cancer.

Dr. Agarwal on Emerging Immunotherapeutic Combinations in Kidney Cancer

August 3rd 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses emerging immunotherapeutic combinations in kidney cancer.

Dr. Herbst on TMB as a Biomarker in NSCLC

August 3rd 2018

Roy S. Herbst, MD, PhD, professor of medicine, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses tumor mutational burden (TMB) as a biomarker in non–small cell lung cancer (NSCLC).

Dr. Wakelee on Single-Agent Immunotherapy in NSCLC

August 2nd 2018

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses single-agent immunotherapy in patients with non–small cell lung cancer (NSCLC).

Early Pembrolizumab/Bevacizumab Study Shows Promise in RCC

August 2nd 2018

Shilpa Gupta, MD, discusses the tolerability and safety of pembrolizumab and bevacizumab in renal cell carcinoma, as well as the future of bladder cancer treatment in the neoadjuvant setting.

FDA Grants Breakthrough Status to Lenvatinib/Pembrolizumab for Endometrial Cancer

August 2nd 2018

The FDA has granted a breakthrough therapy designation to the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) for the treatment of patients with advanced and/or metastatic non–microsatellite instability high/proficient mismatch repair endometrial carcinoma who have progressed after ≥1 prior systemic therapy.

Adjuvant Nivolumab Approved in Europe for Melanoma

July 31st 2018

The European Commission has approved nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease, regardless of BRAF mutation status.

Dr. Makker on Unmet Needs for Patients with Advanced Endometrial Cancer

July 31st 2018

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses unmet needs and treatment challenges for patients with advanced endometrial cancer.

Pembrolizumab Nears European Approval for HNSCC

July 31st 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab (Keytruda) for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed following platinum-based chemotherapy and have a PD-L1 tumor proportion score ≥50%.

EU Panel Backs Frontline Pembrolizumab Combo for Nonsquamous NSCLC

July 30th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of frontline pembrolizumab (Keytruda) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 expression.

Frontline Immunotherapy Poses Fresh Dilemma for Sequencing in NSCLC

July 29th 2018

As the checkpoint inhibitors move into the frontline setting for patients with non–small cell lung cancer, the focus has been placed on the duration of therapy and what to do in the second-line setting following progression.

Dr. Herbst on Intriguing Immunotherapy Combinations in NSCLC

July 28th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses immunotherapy combinations that have potential in non-small cell lung cancer (NSCLC).

Immunotherapy Combos Rapidly Evolving for Lung Cancer

July 28th 2018

The past year has witnessed an explosion in immunotherapy combinations for patients with lung cancer, accompanied by a growing knowledge of biomarkers such as PD-L1 and tumor mutation burden; however, an exact standard of care remains elusive.

Dr. Bunn on Immunotherapy Advances in Small Cell Lung Cancer

July 27th 2018

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care

Dr. Shunyakov on the Impact of Genomics on Personalized Therapy in Oncology

July 27th 2018

Leonid Shunyakov, MD, hematologist/oncologist, Central Care Cancer Center, discusses how genomics have impacted personalized therapy in oncology.